{"classes":[{"categories":[{"measurements":[{"comment":"Values are not estimable as Median was not reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of CI was not estimable","groupId":"OG001","lowerLimit":"2.4","upperLimit":"NA","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Defined as the interval between randomization and the date of the bone marrow blast count of 20% or greater OR the date of the first peripheral blast count of 20% or greater that was subsequently confirmed to have been sustained for at least 8 weeks OR the date of death from any cause, whichever occurs first. OS was summarized using Kaplan-Meier estimates for each treatment arm. The estimates were supplemented by tables of number of events and probability estimates at several timepoints","dispersionType":"95% Confidence Interval","groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"OG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria. Treatment groups were defined according to the treatment assignment at the time of randomization.","reportingStatus":"POSTED","timeFrame":"From randomization until death from any cause","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Years"}